Bank of America Securities analyst Graham Parry maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) yesterday and set a ...

progresses with its promising mRNA-based influenza vaccine in collaboration with GlaxoSmithKline, it's important to consider the company's financial health and market performance. InvestingPro ...

Sensex, Nifty, Share Prices Highlights: The benchmark equity indices closed on a higher note during Monday’s trading session.

The Indian pharmaceuticals market continued to report mid-single-digit growth in August, as sales grew 6.3% annually, ...

The Nigerian naira has plunged hard in the past few months and is now sitting at its all-time low against the US dollar.

Following his inauguration as President of Nigeria in May 2023, Bola Tinubu announced in his inaugural address that his ...

As of September 19, 2024, GSK plc (ADR) had a $87.5 billion market capitalization ... the bottom 20% of the stock universe receive Growth Grades of F, considered Very Weak, while those in the top 20% ...

In final trading hours, the market ... that the PSX saw a "weak start with the KSE-100 remaining below 79,000." Some 35 stocks rose while 63 fell with Hub Power (+5.55%), GlaxoSmithKline (+10% ...

As CureVac N.V. (NASDAQ:CVAC) progresses with its promising mRNA-based influenza vaccine in collaboration with GlaxoSmithKline, it's important to consider the company's financial health and market ...

Markets in Asia-Pacific region slumped on Wednesday morning mirroring similar moves on Wall Street a day before as weak US economic data stoked recession ... its steepest decline since the Aug. 5 ...

They are Kimberly-Clark, Procter & Gamble (P&G), GlaxoSmithKline Consumer (GSK) Nigeria, Equinor, Sanofi, and Bolt Food. Analysts blame the fall of corporate taxes on the exodus of multinationals in ...

Analyst Graham Parry of Bank of America Securities maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), retaining the ...